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The regulation of vascular smooth muscle cell tone by
the vascular endothelium was initially described by Furch-
gott and Zawadzki, suggesting the existence of an endo-
thelium-derived relaxing factor (EDRF) acting through
cGMP, which was later identified as nitric oxide (NO)
(see reference [1] for review). Since then, other actions of
NO such as control of cell growth, blood cell–endothelial
cell interactions, immunomodulatory functions, and anti-
aggregatory effects have been described [2]. In addition to
NO and cyclooxygenase products, a third endothelium-
derived principle, namely hyperpolarization of vascular
smooth muscle cells in response to an endothelium-
derived hyperpolarizing factor (EDHF), has been identi-
fied [3]. Production and bioactivity of endothelial factors
are disturbed in cardiovascular diseases, and endothelium-
dependent dilator mechanisms are counteracted by vaso-
constrictory prostanoids that contribute to abnormal vas-
cular function [4].
In this issue of Cardiovascular Research, Kawabata et
al. report that activating peptides of the protease-activated
receptor 2 (PAR2), namely trypsin and SLIGRL, cause
endothelium-dependent relaxation by activating NO and
EDHF pathways in rat mesenteric arteries in vitro. The
authors show that gap junctions, but not epoxyeicosatrie-
noic acids, hydrogen peroxide, or K+ are involved in the
release of EDHF in response to activation of PAR2.
Moreover, vascular contractions due to an activating pep-
tide of the protease-activated receptor 1 (TFLLR) were
observed after inhibition of EDHF and NO or after
endothelium removal.0008-6363/$ - see front matter D 2004 European Society of Cardiology. Publishe
doi:10.1016/j.cardiores.2004.01.008
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activated receptors
The protease thrombin is generated during activation of
coagulation and converts fibrinogen to soluble fibrin [5].
In addition, thrombin signals directly to endothelial cells,
vascular smooth muscle cells (VSMCs), platelets, fibro-
blasts and other cell types by cleaving protease-activated
receptors (PARs), which belong to the G-protein-coupled
receptor family [6]. The discovery of the first PAR, namely
PAR1, provided a new paradigm for receptor activation
[7]. Since then, three other PARs have been cloned and
shown to play a role in cellular responses to vascular
injury, inflammation and wound healing. Thrombin acts as
an agonist on PAR1, PAR3, and PAR4 with different
potencies [6] whereas PAR2 is activated by both trypsin
and the thrombin-cleaved PAR1. Moreover, several throm-
bin receptor-activating peptides (TRAPs) also activate
PARs [6]. The binding of a PAR agonist to the receptor
is irreversible once the receptor is cleaved, and it is
therefore rather unlikely that these pathways are ‘‘routine-
ly’’ involved in cellular signaling, particularly since the
level of expression widely differs in various vascular cell
types. Interestingly, PARs are not only expressed in
healthy vascular cells but also in atherosclerotic plaques
and after vascular injury, indicating an important role in
response to injury and inflammatory processes [5]. Al-
though most of the published data suggest not only a
pathophysiological but also a physiological role for throm-
bin receptors in regulation of cardiovascular function, mice
deficient in PAR1 or PAR2 both exhibit normal cardiac
function, blood pressure levels and vasomotor responses to
acetylcholine and angiotensin II [8,9].2. PAR1 and vascular function: role of the endothelium
Kawabata et al. investigated the vascular response to a
PAR1-activating peptide (TFLLR) and found that this
peptide caused only a small NO-dependent relaxation in
precontracted rat aortic rings but a substantial contractiond by Elsevier B.V. All rights reserved.
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oxide synthase (NOS) inhibition. However, in the rat
superior mesenteric artery PAR1 causes only a weak
contraction in quiescent rings that is substantially increased
by endothelium removal or inhibition of NO- and EDHF-
dependent pathways. Additionally, the authors provide
evidence suggesting that superoxide does not play a role
for these responses by using superoxide dismutase (SOD).
In contrast to the findings by Kawabata et al. other studies
demonstrated that thrombin and TRAPs cause a substantial
endothelium-dependent relaxation of the aorta and coro-
nary artery from different species [10–14]; these effects
appear to be mainly mediated by cyclooxygenase products
and NO [11,14]. Interestingly, after removal of the endo-
thelium thrombin caused contractile responses in coronary
arteries as observed in the present study [11,14], which
may be due to PAR1-linked increases in vascular smooth
muscle cell Ca2 + flux [15,16]. Additionally, contractile
responses after PAR1 activation have been described even
in the presence of an intact endothelium in human umbil-
ical and placental arteries [17], in line with Kawabata et al.
Taken together, these findings suggest that PAR1-mediated
release of endothelium-derived contracting factors
(EDCFs) may at least in part be responsible for the
observed vascular contractions.
So what is the nature of these EDCFs? It has been shown
that the endothelium produces endothelin-1 (ET-1), prosta-
glandin H2/thromboxane A2, and superoxide anion under
certain conditions in response to other vasoactive substances
[1,18]. Although the authors demonstrated that superoxide
anion is not involved in the contractile responses observed,
a possible role for prostaglandin H2/thromboxane A2 or ET-
1 was not investigated. Indeed, this has been demonstrated
for PAR1 in the renal artery [19] and for PAR2 as discussed
below [20,21]. It is noteworthy that thromboxane A2 and its
receptor have been shown to mediate thrombin-induced
contractions in endothelium-denuded human arteries [22].
Moreover, thrombin also facilitates production and release
of ET-1 [23,24], which could also explain the PAR1-
mediated contractions observed by Kawabata et al. The fact
that PAR1 is activated at low thrombin concentrations
suggests a pathophysiological role for this receptor based
on the observations made in these experimental studies. The
data discussed above indicate functional differences of
PAR1 on endothelial cells and VSMCs depending on the
vascular bed investigated. Furthermore, it has been shown
that agonists of PAR1 cause a biphasic vascular response,
including both relaxation and contraction [19].3. A link between PAR2 and EDHF?
Trypsin and PAR2-activating peptides can induce endo-
thelium-dependent relaxation in rat [25] and rabbit aorta
[20] as well as in other arteries [26–29], which is mainly
due to NO. Kawabata et al. also evaluated the role of PAR2for endothelium-dependent vasoreactivity in isolated rat
mesenteric artery and aorta by using SLIGRL and trypsin.
The results of these experiments show that these agonists
lead to a substantial NO-dependent relaxation in rat aorta
and cause complete endothelium-dependent relaxation in rat
mesenteric arteries that is only in part inhibited by NG-nitro-
L-arginine methyl ester (L-NAME, a nonselective inhibitor
of NOS) and indomethacin (a nonselective inhibitor of
cyclooxygenase). Thus, the authors also present evidence
that another endothelium-dependent principle is involved in
PAR2-mediated signaling in the vascular wall of resistance
arteries. Kabawata et al. demonstrate that the vasodilatory
effect in response to PAR2 activation involves EDHF and
gap-junction signaling. These observations could be
explained by the caliber of resistance arteries, in line with
previous data showing that the contribution of EDHF for
endothelium-dependent relaxation increases with decreasing
vessel diameter [30]. Similar observations were made in
mice with atherosclerosis [31], and EDHF may contribute to
abnormal endothelial vasoreactivity in patients with athero-
sclerosis [32]. Kawabata et al. elegantly demonstrate a role
for EDHF in the PAR2-mediated vasorelaxation in the
mesenteric artery by blocking small-, intermediate- and
large-conductance Ca2 +-sensitive K+ channels. The authors
also show involvement of gap junctions since the relaxant
response was blocked by carbenoxolone, an inhibitor of gap
junctional intercellular communication. The findings of
Kawabata et al. are in agreement with a recent study
suggesting a role for EDHF in PAR2-mediated vasodilation
of coronary arteries [33] that may also be functional in other
vascular beds such as the gastric artery [34].
PAR2-activation did not cause contractions in rat mesen-
teric artery rings as reported by Kawabata et al., although
PAR2-mediated vasoconstriction has been observed in dif-
ferent vascular beds and appears to be both endothelium
dependent [20,21] as well as endothelium independent [35].
This endothelium-dependent vasoconstrictor response is pos-
sibly due to a yet unidentified contractile factor (EDCF) from
human endothelial cells and may be mediated via a novel
PAR2 receptor subtype, at least in human umbilical veins
[21].
The findings by Kawabata et al. demonstrate a distinct
role for EDHF and gap junction signaling in PAR2-
mediated vascular responses in mesenteric resistance arter-
ies. Whether these mechanisms are important for maintain-
ing vascular integrity in diseases such as atherosclerosis
[32], arterial thrombosis, or restenosis remains to be
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